Gain Therapeutics $GANX

Health Care · NASDAQ

Maryland
$1.00
-0.05 (-4.86%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 5, 2026, the first target we tracked for GANX.

Gain Therapeutics (GANX) is trading down at $1.00 (-4.86%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.

IPO: March 18, 2021 · $11.00 offering · NASDAQ

Analyst price targets on GANX

One firm's current price target on Gain Therapeutics: $5 — 401% above the current $1. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 5, 2026 FirmBTIG RatingBuy · reiterates Targetat $1.69 · $5 +196% Horizonby Oct 2027 StatusOpen

Entry price $1.69, the close nearest Oct 5, 2026, when the target was reported; the target is +196% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 5, 2027.

Source BTIG reiterates Buy on Gain Therapeutics stock on trial data Investing.com · Oct 5, 2026 · opens the publisher's site
BTIG reiterated a Buy rating and $5.00 price target on Gain Therapeutics

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Gain Therapeutics revenue & net income history (FY2020–FY2025)

RevenueNet incomeNet margin (right axis, %)
$165.0K−$11.1M−$22.3MFY2020 revenue: $28.9KFY2020 net income: −$3.58M · Net margin −12387.7%'20FY2021 revenue: $165.0KFY2021 net income: −$13.9M · Net margin −8418.9%'21FY2022 revenue: $140.1KFY2022 net income: −$17.6M · Net margin −12555.1%'22FY2023 revenue: $55.2KFY2023 net income: −$22.3M · Net margin −40354.3%'23FY2024 net income: −$20.4M'24FY2025 net income: −$20.2M'25−100%−80%−60%−40%−20%0%FY2020 net margin: −12387.7% (off the scale, which stops at −100.0%)FY2021 net margin: −8418.9% (off the scale, which stops at −100.0%)FY2022 net margin: −12555.1% (off the scale, which stops at −100.0%)FY2023 net margin: −40354.3% (off the scale, which stops at −100.0%)
Gain Therapeutics annual financial statements
FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$28.9K$165.0K$140.1K$55.2K——
Growth (year over year)—+471.3%−15.1%−60.6%——
Operating income−$3.48M−$13.8M−$17.8M−$22.3M−$20.4M−$18.7M
Operating margin−12047.5%−8379.8%−12688.1%−40328.3%——
Net income−$3.58M−$13.9M−$17.6M−$22.3M−$20.4M−$20.2M
Net margin−12387.7%−8418.9%−12555.1%−40354.3%——
EPS (diluted)−$1.33−$1.37−$1.48−$1.71−$0.89−$0.61
Balance sheet
Cash and equivalents$7.49M$36.9M$7.31M$11.8M$10.4M$20.8M
Total assets$9.60M$39.0M$24.1M$18.6M$12.1M$22.8M
Total liabilities$3.40M$4.17M$5.22M$6.03M$4.78M$4.25M
Long-term debt$715.7K$590.5K$495.3K$449.1K$328.3K$300.1K
Shareholders' equity$6.20M$34.8M$18.9M$12.6M$7.34M$18.6M
Cash flow
Operating cash flow−$3.24M−$12.4M−$14.7M−$18.9M−$18.9M−$18.5M
Capital expenditure$20.8K$94.2K$119.0K$15.4K$22.5K—
Free cash flow−$3.26M−$12.5M−$14.8M−$18.9M−$18.9M—

From Gain Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Gain Therapeutics in the news

Nov 17, 2026 GlobeNewswire Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
Nov 10, 2026 GlobeNewswire Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Oct 5, 2026 Investing.com BTIG reiterates Buy on Gain Therapeutics stock on trial data Target

About Gain Therapeutics

Headquarters
Bethesda, Maryland From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →